Pharmaceutical groups Sanofi and GlaxoSmithKline have said the rollout of their Covid-19 vaccine will be delayed until at least the last quarter of 2021 because the initial version failed to produce a strong immune response in the elderly.
The two companies announced Friday that the first test results showed “an immune response comparable to that of patients who have recovered from Covid-19 in adults aged 18 to 49, but a weak immune response in the elderly probably due to insufficient concentration of the antigen. ”
They said they plan to conduct further studies with an improved antigen formulation and the product is now expected to be available in the fourth quarter of next year, provided the development plan is completed.
The two companies said they were disappointed with the results of the first trials of the vaccine. “Our goal now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, so that it makes a significant contribution to the prevention of Covid-19,” said Roger Connor, president by GSK Vaccines.